Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
July 28 2023 - 7:30AM
Business Wire
Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN),
today announced a data update from the phase 1 expansion cohort of
botensilimab (multifunctional CTLA-4 antibody) in combination with
balstilimab (PD-1 antibody) for patients with advanced, refractory
sarcomas has been selected for an oral presentation at the upcoming
ESMO Congress, to be held October 20 – 24, 2023 in Madrid,
Spain.
Presentation Details:
Abstract Title: Efficacy and safety of botensilimab (BOT)
plus balstilimab (BAL) in patients (pts) with refractory metastatic
sarcoma (NCT03860272) Abstract Number: 1919MO Presenting
Author: Breelyn A. Wilky, MD, Director of Sarcoma Medical
Oncology, Deputy Associate Director for Clinical Research,
University of Colorado Cancer Center Presentation Date and
Time: 10/21/2023, 10:15pm – 11:45pm CEST
Data presented at the conference will be available to view in
the publications section of the Agenus website
(https://agenusbio.com/publications) following the ESMO
Conference.
About Botensilimab
Botensilimab, an investigational multifunctional CTLA-4 antibody,
is designed to extend immunotherapy benefits to "cold" tumors,
which have not historically responded to standard of care or other
investigational therapies. Besides binding to the CTLA-4 receptor,
its Fc-enhanced structure induces a memory immune response,
downregulates regulatory T cells, and activates T cells, thereby
enhancing immune responses. Approximately 600 patients have been
treated with botensilimab in phase 1 and phase 2 clinical trials.
Botensilimab alone, or in combination with Agenus’ PD-1 antibody,
balstilimab, has shown clinical responses across nine metastatic,
late-line cancers. For more information about botensilimab trials,
visit www.clinicaltrials.gov with the identifiers NCT05608044,
NCT05630183, and NCT05529316.
About Agenus Agenus is a
leading immuno-oncology company targeting cancer and infectious
diseases with a comprehensive pipeline of immunological agents. The
company’s mission is to expand patient populations benefiting from
cancer immunotherapy through combination approaches, using a broad
repertoire of antibody therapeutics, adoptive cell therapies
(through MiNK Therapeutics) and adjuvants (through SaponiQx).
Agenus is headquartered in Lexington, MA. For more information,
visit www.agenusbio.com or follow us on LinkedIn and Twitter
@agenus_bio.
Forward Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements relating to the use of
botensilimab and balstilimab, for instance, statements regarding
therapeutic benefit and efficacy, mechanism of action (including
validation of mechanism of action), potency, durability, and safety
profile (including the absence of specific toxicities) of the
Company’s therapeutic candidates; and any other statements
containing the words "may," "believes," "expects," "anticipates,"
"hopes," "intends," "plans," "forecasts," "estimates," "will,"
“establish,” “potential,” “superiority,” “best in class,” and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our most
recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K
filed with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230728758873/en/
Investor Contact Zack Armen
Head of Investor Relations 917-362-1370
zack.armen@agenusbio.com
Media Contact 781-674-4784
communications@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024